Korea Stock Market Insights

Tag: Green Chemicals

  • (285130) SK Chemicals IR Q3 2025: Deep Dive on Earnings, Stock & Future Outlook for Investors

    (285130) SK Chemicals IR Q3 2025: Deep Dive on Earnings, Stock & Future Outlook for Investors

    Dear Investors, the upcoming SK Chemicals IR session, scheduled for November 6, 2025, represents a pivotal moment for the company and its stakeholders. This event will provide a crucial look into the Q3 2025 earnings, strategic initiatives, and the overall health of the business. For current and prospective investors, this session is more than a standard financial report; it’s a window into the company’s resilience and future growth trajectory amidst a challenging global market. This analysis will break down what to expect from the SK Chemicals earnings announcement, its potential impact on the SK Chemicals stock price, and the key metrics that demand your attention.

    The company has formally announced this event, as detailed in their Official Disclosure (DART), underscoring its commitment to transparency with SK Chemicals investors.

    Unpacking the Q3 2025 SK Chemicals IR Announcement

    On November 6, 2025, at 9:00 AM, SK Chemicals Co., Ltd. will host its Investor Relations (IR) session. With a market capitalization of approximately KRW 1,167.7 billion, the stakes are high. This session aims to deliver a transparent overview of the Q3 2025 financial performance, provide updates on the current business status, and outline key strategic priorities moving forward. The core objective is to reinforce investor confidence by presenting a clear and data-driven picture of the company’s present stability and future ambitions.

    Analyzing SK Chemicals’ Fundamentals

    SK Chemicals has built its foundation on a robust and diversified business portfolio, primarily split between its Green Chemicals and Life Science divisions. This structure has proven resilient, enabling the company to increase sales and achieve a turnaround to operating profit in the first half of 2025, demonstrating positive momentum.

    The Green & Life Science Pillars: A Dual Engine for Growth

    • •Green Chemicals Division: This segment is a significant growth driver, fueled by high-value, eco-friendly materials like Copolyester, ECOZEN, and SKYPET CR. The chemically recycled PET resin business, in particular, aligns perfectly with global ESG trends, positioning it as a critical engine for sustainable growth. For more on this trend, see the latest market analysis from leading industry reports.
    • •Life Science Division: The bio business continues to show strong performance, supported by self-developed pharmaceuticals and the impressive vaccine sales from its affiliate, SK Bioscience. This division provides both stability and high-growth potential.

    Navigating Financial Headwinds

    Despite its strengths, the company is not immune to risks. While its consolidated debt-to-equity ratio remains stable at 85.10%, key profitability metrics like ROE (1.77%) and ROA (0.54%) are relatively low. This is largely due to strategic investments in R&D and new business ventures. A key focus for investors will be the company’s plan to improve cash flow and demonstrate a clear return on these crucial investments.

    The core challenge for SK Chemicals is balancing long-term strategic investment in high-growth areas like sustainable materials with the short-term need to enhance profitability and shareholder value. This IR will be a test of their ability to communicate that balance effectively.

    Potential Stock Impact: What Investors Should Watch For

    The IR session’s content will undoubtedly influence the SK Chemicals stock performance. A clear, confident presentation of strong earnings and a compelling growth strategy could boost investor sentiment. Conversely, any signs of weakness or failure to meet market expectations could trigger a negative reaction. For a deeper look at portfolio diversification, you can read our guide on building a resilient investment strategy.

    Key Questions for the Upcoming SK Chemicals Earnings Call

    Informed SK Chemicals investors should listen for answers to the following critical questions:

    • •Profitability by Segment: How are the Green Chemicals and Life Science divisions performing individually in terms of sales and profit margins?
    • •Sustainable Materials Growth: What is the specific commercialization timeline and projected revenue for chemically recycled products like SKYPET CR?
    • •Life Science Pipeline: Are there any updates on the R&D pipeline? What is the growth outlook for SK Bioscience’s CDMO business?
    • •Risk Management: What specific measures are being taken to mitigate the impact of volatile oil prices, exchange rates, and rising interest rates?
    • •Capital Allocation: How does the company plan to allocate capital between new investments and returning value to shareholders?

    The answers provided during this SK Chemicals IR will be instrumental in re-evaluating the company’s investment thesis. A thorough and critical analysis of the information presented is highly recommended for making sound financial decisions.

    Frequently Asked Questions (FAQ)

    When is the SK Chemicals IR session?

    SK Chemicals will host its Investor Relations (IR) session for the Q3 2025 earnings release on November 6, 2025, at 9:00 AM.

    What are SK Chemicals’ main business segments?

    The company’s two primary business segments are the Green Chemicals Biz (eco-friendly materials) and the Life Science Biz (pharmaceuticals and bio-business).

    What are the potential risks for SK Chemicals investors?

    Key risks include macroeconomic factors like volatility in oil prices and exchange rates, as well as currently low profitability metrics (ROE, ROA) due to heavy investment in future growth initiatives.

    (285130) SK Chemicals IR Q3 2025: Deep Dive on Earnings, Stock & Future Outlook for Investors 관련 이미지
  • (285130) SK Chemicals Earnings Surprise: 2025 Results, Stock Analysis & Investment Outlook

    (285130) SK Chemicals Earnings Surprise: 2025 Results, Stock Analysis & Investment Outlook

    The latest SK Chemicals earnings report for 2025 has sent a wave of optimism through the market. With provisional results dramatically outperforming forecasts, investors are now keenly focused on what this ‘earnings surprise’ signifies for the company’s future and the trajectory of SK Chemicals stock. This comprehensive analysis will dissect the key figures, explore the performance of its core business segments, and provide a strategic outlook for potential investors.

    Unpacking the SK Chemicals 2025 Results: A Stunning Turnaround

    On November 5, 2025, SK Chemicals Co., Ltd. released its provisional consolidated operating results, which didn’t just meet but shattered market expectations. The successful return to profitability marks a pivotal moment for the company. Here are the standout figures:

    • •Revenue: KRW 609.9 billion, an impressive 8.04% increase over the forecasted KRW 566.5 billion.
    • •Operating Profit: KRW 15.1 billion, a staggering 208.16% surge compared to the KRW 4.9 billion forecast, marking a successful turnaround to profitability.
    • •Net Profit: KRW 42.9 billion, an astronomical 464.47% leap beyond the projected KRW 7.6 billion.

    The most significant takeaway is the robust turnaround in operating profit. It demonstrates underlying operational efficiency and portfolio strength, even amidst challenging global economic conditions. This is a clear signal of resilience.

    Analysis of Core Business Segments

    Two primary divisions drove this remarkable performance. Understanding their individual contributions is key to evaluating the long-term potential of SK Chemicals stock.

    🌱 The Green Chemicals Business: A Sustainable Growth Engine

    Despite facing pressures from volatile raw material prices and a global economic slowdown, the Green Chemicals business was a cornerstone of the profit turnaround. The company’s strategic focus on a diversified portfolio of eco-friendly materials and an expanded customer base paid off. Key initiatives, such as the commercialization of chemically recycled PET resin, underscore a commitment to the circular economy—a rapidly growing market. While overall revenue in this segment saw a slight dip due to reduced consumption in China, its contribution to profitability proves the strategy’s effectiveness. For more on this trend, you can explore our analysis of the sustainable materials market.

    🔬 The Life Science Business: Resilience and Future Potential

    The Life Science business presented a mixed but ultimately promising picture. The Pharma division delivered consistent growth by successfully launching modified new drugs and defending the market share of its existing products. Conversely, its subsidiary SK Bioscience faced a temporary downturn as demand for its COVID-19 vaccine CMO/CDMO (Contract Development and Manufacturing Organization) services waned. However, strategic moves like the acquisition of IDT Biologika signal a strong push into the European market and a broader expansion of its CDMO capabilities, positioning it as a significant long-term growth driver.

    Investment Outlook: Navigating Risks and Opportunities

    This ‘earnings surprise’ undoubtedly creates powerful short-term momentum. However, a prudent investor must weigh this against persistent macroeconomic headwinds and internal financial metrics. The positive sentiment could drive the SK Chemicals stock price higher, but future growth must meet these newly elevated expectations.

    Key Factors to Monitor

    • •Positive Catalysts: Continued growth in the eco-friendly materials market, expansion of SK Bioscience’s CDMO pipeline, and steady performance from the Pharma segment.
    • •Potential Risks: Ongoing volatility in oil prices and exchange rates, as noted by financial authorities like Reuters, and a relatively high consolidated debt ratio of 114.65%, which presents a financial health challenge.

    Conclusion: An Action Plan for Investors

    The stellar SK Chemicals 2025 results signal a potential inflection point. The company has demonstrated its ability to navigate a complex environment and deliver profitability through strategic portfolio management. While macroeconomic risks and the need for financial deleveraging remain, the long-term growth narrative in its green and bio-based businesses is compelling.

    Investors should interpret this event as a strong positive sign but maintain a long-term perspective. Closely monitoring the company’s progress in improving its financial structure and capitalizing on its growth drivers will be crucial. For complete transparency, the company’s full report is available in the Official Disclosure on the DART system. A patient, long-term approach focused on fundamental value creation appears to be the most prudent strategy.

    (285130) SK Chemicals Earnings Surprise: 2025 Results, Stock Analysis & Investment Outlook 관련 이미지
  • (285130) SK Chemicals Q3 Earnings Analysis (285130): Surprise 510% Profit Beat Explained

    (285130) SK Chemicals Q3 Earnings Analysis (285130): Surprise 510% Profit Beat Explained

    The latest SK Chemicals Q3 earnings report for 2025 presents a fascinating paradox for investors and market analysts. On November 5, 2025, SK Chemicals Co., Ltd. (KRX: 285130) released provisional figures that defied expectations. While total revenue significantly missed consensus estimates, the company delivered an astonishing ‘earnings surprise’ with operating and net profits soaring far beyond predictions. This disconnect raises critical questions: what fueled this incredible profitability, and what does it mean for the future of the SK Chemicals stock?

    This comprehensive SK Chemicals analysis will dissect the Q3 financial results, exploring the performance of its core business segments—Green Chemicals and Life Science. We will examine the macroeconomic headwinds, unpack the drivers behind the profit surge, and provide a forward-looking perspective for anyone considering an investment in this dynamic company.

    SK Chemicals Q3 2025 Earnings: The Headline Numbers

    The provisional Q3 results showcased a stark contrast between top-line revenue and bottom-line profitability. Here is a summary of the key figures compared to market consensus estimates, based on the Official Disclosure:

    • •Revenue: KRW 371.5 billion, a significant 35% miss below the market estimate of KRW 569.4 billion.
    • •Operating Profit: KRW 29.9 billion, a massive 510% beat above the market estimate of KRW 4.9 billion.
    • •Net Profit: KRW 24.7 billion, a robust 225% beat above the market estimate of KRW 7.6 billion.

    Despite a significant revenue shortfall, SK Chemicals demonstrated remarkable operational efficiency, driving a 510% surge in operating profit. This highlights the strength of its high-margin Life Science division and disciplined cost management.

    Dissecting the Segments: A Tale of Two Businesses

    To understand these contradictory results, we must analyze the performance of SK Chemicals’ two primary business pillars.

    Green Chemicals Biz: The Revenue Headwind

    The Green Chemicals segment, which produces high-performance copolyesters and other eco-friendly materials, is the likely source of the revenue shortfall. While demand for sustainable materials is structurally strong, this segment faced several near-term challenges. A slowdown in Chinese consumption, a key export market, coupled with increased regional competition likely compressed sales volumes. Furthermore, as we will discuss, volatile raw material prices put pressure on margins, making it difficult to grow the top line even with steady underlying demand. This performance seems to be an industry-wide issue, as detailed in this deep dive into the global specialty chemicals market.

    Life Science Biz: The Profit Engine for Q3 Earnings

    The Life Science division was the undisputed star of the quarter and the primary driver behind the exceptional SK Chemicals profit beat. This segment, which includes proprietary drugs and the vaccine/CDMO business of its subsidiary SK bioscience, showcased its high-margin potential. The outperformance was likely driven by a combination of factors:

    • •High-Margin Contracts: Successful execution of lucrative CDMO (Contract Development and Manufacturing Organization) contracts likely contributed significantly to the bottom line.
    • •Strong Vaccine Sales: Better-than-expected sales from SK bioscience’s premium vaccine portfolio bolstered profitability.
    • •Operational Excellence: Rigorous cost control and efficiency measures across the division amplified the financial impact of its revenue streams.

    Macroeconomic Factors at Play

    External economic forces added another layer of complexity to the 285130 earnings. The interplay between currency fluctuations and raw material costs was critical.

    • •Currency Volatility (KRW/USD): A volatile exchange rate during Q3 created a dual impact. While a weaker Won can make exports more competitive, it also increases the cost of imported raw materials, directly affecting the Green Chemicals segment’s profitability.
    • •Crude Oil Prices (WTI): As a key feedstock for chemical production, fluctuating WTI prices directly impact production costs. Navigating this volatility was crucial for preserving margins. According to authoritative sources like Bloomberg, energy market instability was a key theme in the second half of the year.

    Investment Outlook and Key Considerations

    For investors evaluating the SK Chemicals stock, the Q3 report provides several key takeaways for both the short and long term.

    Short-Term Outlook

    The market may react cautiously to the revenue miss, as top-line growth is a critical indicator of market share and demand. However, the powerful earnings beat demonstrates strong management and the resilience of the Life Science portfolio. The stock’s immediate trajectory will likely depend on management’s commentary regarding the sustainability of this high profitability and the recovery timeline for the Green Chemicals segment.

    Long-Term Growth Drivers

    The long-term investment thesis remains compelling. The structural growth in the global biologics market supports the CDMO business, while an aging population boosts demand for vaccines and pharmaceuticals. In the Green Chemicals space, the global push for sustainability provides a powerful tailwind. Investors should monitor the following:

    • •Life Science Pipeline: Progress in drug development and the acquisition of new, high-value CDMO clients.
    • •Green Chemicals Recovery: Signs of stabilization and recovery in the Chinese market and new product innovations.
    • •SK Multi-Utility Impact: The contribution of the new LNG co-generation plant to operational efficiency and cost savings once it becomes fully operational.

    In conclusion, while the revenue decline in the SK Chemicals Q3 earnings warrants attention, the exceptional profitability improvement signals a company with strong operational discipline and a highly valuable Life Science division. Sustainable growth will depend on the market recovery for its chemical business and continued momentum in its pharma and biotech ventures.

    (285130) SK Chemicals Q3 Earnings Analysis (285130): Surprise 510% Profit Beat Explained 관련 이미지

  • SK Chemical Plans ₩240 Billion EB Issuance: Investment Strategy & Outlook



    SK Chemical Plans ₩240 Billion EB Issuance: Investment Strategy & Outlook 대표 차트 이미지






    1. SK Chemical’s EB Issuance: What’s Happening?

    According to a report by Korea Economic Daily on September 4, 2025, SK Chemical is planning to issue ₩240 billion worth of Exchangeable Bonds (EBs) using its subsidiary stakes. While still unconfirmed, this move is expected to significantly impact SK Chemical’s business strategy.

    2. Why Issue EBs?

    SK Chemical is focused on securing growth momentum by investing heavily in its Green Chemicals and Life Science businesses. The funds raised through the EB issuance are expected to be utilized for expansion and R&D in these core business areas. It is also anticipated to improve the company’s financial structure and increase investment capacity.

    3. Impact on Investors

    • Positive Impacts: Business expansion, improved financial structure, re-evaluation of subsidiary value, increased market interest.
    • Negative Impacts: Potential dilution of shareholder value, interest burden, market volatility, subsidiary stake value fluctuations.

    4. SK Chemical’s Current Business Performance

    SK Chemical has shown stable growth in both its Green Chemicals and Life Science businesses. The Green Chemicals business is strengthening its eco-friendly materials portfolio, while the Life Science business is focusing on expanding its vaccine and CDMO businesses. Despite a decrease in sales, the company’s H1 2025 results showed a positive turnaround with operating profit, indicating a positive trend.

    5. Investment Action Plan

    • Confirm Re-disclosure Details: Carefully review the terms of the EB issuance, including size, interest rates, etc.
    • Monitor Subsidiary Performance and Investment Efficiency: Observe how the funds are utilized and the impact on subsidiary value.
    • Watch Macroeconomic Conditions: Pay attention to external factors such as fluctuations in exchange rates, oil prices, and interest rates.
    • Consider Potential Share Dilution: Factor in the potential dilution of shareholder value upon EB conversion when making investment decisions.


    FAQ

    What are Exchangeable Bonds (EBs)?

    EBs are bonds that grant the holder the right to exchange them for shares of a company other than the issuer at maturity.

    How will the EB issuance affect SK Chemical’s stock price?

    In the short term, it could attract investor interest and drive up the stock price. However, in the long term, the increased number of shares from EB conversion could dilute shareholder value.

    What are SK Chemical’s core businesses?

    SK Chemical operates two core businesses: Green Chemicals (eco-friendly materials) and Life Science (bio/vaccines).









    SK Chemical Plans ₩240 Billion EB Issuance: Investment Strategy & Outlook 관련 이미지
    SK Chemical Plans ₩240 Billion EB Issuance: Investment Strategy & Outlook 관련 이미지




  • SK Chemicals Q2 2025 Earnings: Green Chemicals Growth & Investment Strategies

    1. SK Chemicals Q2 Earnings: Key Highlights

    SK Chemicals held its Q2 2025 earnings announcement and management briefing on August 8th. The primary focus of this IR was the continued growth of the Green Chemicals and Life Science businesses, the strategic direction of SK bioscience’s CDMO business, and strategies for navigating the macroeconomic environment.

    2. Growth Drivers and Risks by Business Segment

    2.1 Green Chemicals: Leading the Eco-Friendly Materials Market

    • Positive Factors: Expanding market for eco-friendly materials (bio-polyols, recycled PET), strengthening market dominance in copolyester resins.
    • Risks: Dependence on the Chinese market and intensifying competition, volatility of raw material prices.

    2.2 Life Science: Growth Potential of SK bioscience

    • Positive Factors: Expansion of SK bioscience’s CDMO business, stable pharmaceutical and vaccine portfolio.
    • Risks: Investment burden of SK bioscience, intensifying competition in the CDMO market.

    3. SK Chemicals Investment Strategy: Key Points

    When investing in SK Chemicals, closely monitor Q2 earnings, the turnaround timing and plans for SK bioscience, and strategies for responding to the macroeconomic environment. The growth of the Green Chemicals business and the improvement in profitability of SK bioscience’s CDMO business will be important indicators for investment decisions.

    4. Conclusion: Long-Term Growth Outlook, Short-Term Volatility Caution

    SK Chemicals holds long-term growth potential, centered around its Green Chemicals and Life Science businesses. However, macroeconomic uncertainties and the investment burden of SK bioscience may cause short-term stock price volatility. Investors should make cautious investment decisions by comprehensively considering the IR announcements and market conditions.

    Frequently Asked Questions (FAQ)

    What are SK Chemicals’ main businesses?

    SK Chemicals operates primarily in Green Chemicals (eco-friendly materials, copolyesters, etc.) and Life Science (SK bioscience, pharmaceuticals, vaccines).

    What is SK bioscience’s CDMO business?

    CDMO (Contract Development and Manufacturing Organization) is a business that undertakes the development and production of biopharmaceuticals. SK bioscience is securing future growth engines by expanding its CDMO business.

    What should investors be cautious of when investing in SK Chemicals?

    Consider macroeconomic volatility, the investment burden of SK bioscience, and dependence on the Chinese market. Also, pay close attention to the intensifying competition in the eco-friendly materials and CDMO markets.

  • SK Chemicals Q2 2025 Earnings Shock: What Investors Need to Know

    1. What Happened?

    SK Chemicals reported Q2 2025 revenue of KRW 596.9 billion, exceeding expectations by 8%. However, operating profit came in at a disappointing KRW -1 billion, significantly below estimates. Net income showed a positive turn, reaching KRW 14 billion.

    2. Why Did This Happen?

    Several factors likely contributed to the weak operating profit, including fluctuations in raw material prices, changes in order intake, and intensified competition in the CDMO business. The decline in operating rate at SK bioscience’s Andong L House facility and increased competition in the global CDMO market appear to have particularly impacted profitability.

    3. What Should Investors Do?

    While short-term stock price volatility is possible, the long-term growth potential of SK Chemicals’ Green Chemicals and Life Science businesses remains promising. Investors should focus on the company’s fundamental value and long-term growth prospects rather than reacting to short-term market fluctuations.

    4. Investor Action Plan

    • Seek additional information regarding the reasons for the decline in operating profit.
    • Monitor the growth strategies of the Green Chemicals and Life Science businesses.
    • Pay close attention to changes in the macroeconomic environment (exchange rates, oil prices, interest rates).
    • Evaluate the company’s value and make investment decisions based on a long-term perspective.

    FAQ

    What were SK Chemicals’ Q2 2025 results?

    SK Chemicals reported revenue of KRW 596.9 billion, operating profit of KRW -1 billion, and net income of KRW 14 billion for Q2 2025.

    What caused the earnings shock?

    The earnings shock is likely attributed to fluctuations in raw material prices, changes in order intake, and intensified competition in the CDMO market.

    Should I invest in SK Chemicals?

    While short-term stock price fluctuations are possible, the long-term growth potential of the Green Chemicals and Life Science businesses should be considered. Investment decisions should be made carefully based on individual assessment.

  • SK Chemicals Q2 2025 Earnings: A Surprise Beat and Investment Outlook

    1. SK Chemicals Q2 2025 Earnings: Decoding the Surprise Beat

    SK Chemicals reported Q2 2025 revenue of KRW 384 billion (down 31% YoY), operating profit of KRW 25.1 billion (up 1,469% YoY), and net profit of KRW 15.7 billion (up 848% YoY). Despite revenue falling short of market expectations, operating and net profits delivered a substantial positive surprise. This is attributed to improved cost management and lower raw material prices within the Green Chemicals Biz. segment.

    2. Segment Performance: Green Chemicals vs. Life Science

    Green Chemicals Biz., contributing 71.3% of consolidated revenue, continued its solid growth trajectory. The segment’s focus on eco-friendly materials and circular economy aligns with ESG trends, securing long-term growth potential. Conversely, Life Science Biz., despite growth in SK bioscience’s CDMO business, recorded a loss due to substantial R&D and facility investments.

    3. Key Investment Takeaways and Action Plan

    Key factors to consider when investing in SK Chemicals include analyzing the reasons behind the revenue shortfall, the visibility of Life Science Biz.’s profitability improvement, fluctuations in exchange rates and oil prices, and overall macroeconomic uncertainties. While short-term momentum driven by the earnings surprise is expected, a long-term perspective requires careful monitoring of these factors. Investors should focus on the steady growth of Green Chemicals Biz. and the potential of Life Science Biz., while adopting a prudent investment strategy aligned with market conditions.

    What were the key highlights of SK Chemicals’ Q2 2025 earnings?

    While revenue missed estimates, the company delivered a significant earnings surprise with operating and net profits exceeding expectations. The strong performance of Green Chemicals Biz. was a key driver.

    Why did SK Chemicals’ Life Science Biz. report a loss?

    Despite growth in SK bioscience’s CDMO business, substantial investments in R&D and facilities resulted in a loss. However, the segment’s long-term growth potential remains high.

    What are the key risks to consider when investing in SK Chemicals?

    Investors should carefully monitor factors such as the reasons for the revenue shortfall, the path to profitability for Life Science Biz., fluctuations in exchange rates and oil prices, and overall macroeconomic uncertainty.

  • SK Chemicals Interim Dividend Announcement: Investment Strategy and Future Outlook

    SK Chemicals Interim Dividend: KRW 400 per share

    SK Chemicals has declared an interim cash dividend of KRW 400 per share for both common and preferred stock. The record date is August 8, 2025.

    Why is the Dividend Decision Important?

    This interim dividend provides investors with short-term cash flow. Despite the low dividend yield of 0.5%, it is considered appropriate given SK Chemicals’ robust financial health. The dividend payout ratio of approximately 69% can be interpreted as a strategy to return profits to shareholders while securing reinvestment potential.

    How Will the Dividend Decision Affect the Stock Price?

    Dividend announcements typically have a positive impact on stock prices. However, in this case, the impact may be limited due to the low dividend yield and the possibility that it was already anticipated by the market. Analysis of past stock data indicates that SK Chemicals’ stock price is sensitive to market conditions and corporate fundamentals. Therefore, the volatility of macroeconomic indicators and the possibility of changes in fundamentals should be considered.

    SK Chemicals Investment Strategy: Green Chemicals & Life Science

    • Green Chemicals: Despite falling raw material prices and concerns about an economic downturn, the increasing demand for eco-friendly materials is a growth driver for SK Chemicals. Investors should monitor external factors such as crude oil prices, exchange rate fluctuations, and the Baltic Dirty Tanker Index.
    • Life Science: The aging society and growth of the bio market are positive factors. However, drug pricing policies, regulatory tightening, and fluctuations in exchange rates and interest rates can act as risk factors.

    Action Plan for Investors

    Rather than expecting a short-term stock price increase, it is important to establish an investment strategy from a long-term perspective. Continuously monitor macroeconomic indicators, industry trends, and government regulations. It’s advisable to make investment decisions based on expert analysis and reports.

    Frequently Asked Questions

    What is SK Chemicals’ interim dividend amount?

    KRW 400 per share for both common and preferred stock.

    When is the record date for the dividend?

    August 8, 2025.

    How will this dividend decision affect the stock price?

    It is likely to have a positive impact, but the increase may be limited due to the low dividend yield and the possibility it was already anticipated.